TITLE

Diagnosis and Management of Waldenström Macroglobulinernia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

AUTHOR(S)
Ansell, Stephen M.; Kyle, Robert A.; Reeder, Craig B.; Fonseca, Rafael; Mikhael, Joseph R.; Morice, William G.; Bergsagel, P. Leif; Buadi, Francis K.; Colgan, Joseph P.; Dingli, David; Dispenzieri, Angela; Greipp, Philip R.; Habermann, Thomas M.; Hayman, Suzanne R.; Inwards, David J.; Johnston, Patrick B.; Kumar, Shaji K.; Lacy, Martha Q.; Lust, John A.; Markovic, Svetomir N.
PUB. DATE
September 2010
SOURCE
Mayo Clinic Proceedings;Sep2010, Vol. 85 Issue 9, p824
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Waldenström macroglobulinemia is a B-cell malignancy with lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M protein (IgM) in the serum. It is incurable with current therapy, and the decision to treat patients as well as the choice of treatment can be complex. Using a risk-adapted approach, we provide recommendations on timing and choice of therapy. Patients with smoldering or asymptomatic Waldenström macroglobulinemia and preserved hematologic function should be observed without therapy. Symptomatic patients with modest hematologic compromise, IgM-related neuropathy that requires therapy, or hemolytic anemia unresponsive to corticosteroids should receive standard doses of rituximab alone without maintenance therapy. Patients who have severe constitutional symptoms, profound hematologic compromise, symptomatic bulky disease, or hyperviscosity should be treated with the DRC (dexamethasone, rituximab, cyclophosphamide) regimen. Any patient with symptoms of hyperviscosity should first be treated with plasmapheresis. For patients who experience relapse after a response to initial therapy of more than 2 years' duration, the original therapy should be repeated. For patients who had an inadequate response to initial therapy or a response of less than 2 years' duration, an alternative agent or combination should be used. Autologous stem cell transplant should be considered in all eligible patients with relapsed disease.
ACCESSION #
53742014

 

Related Articles

  • Hypergammaglobulinaemic Purpura Associated with IgG Subclass Imbalance and Recurrent Infection. Al-Mayouf, S. M.; Ghonaium, A.; Bahabri, S. // Clinical Rheumatology;Nov2000, Vol. 19 Issue 6, p499 

    : We describe a child who initially presented with recurrent infections. He subsequently developed hypergammaglobulinemic purpura but responded well to corticosteroids and hydroxychloroquine.

  • Biologika in Schwangerschaft und Stillzeit. Fischer-Betz, R.E.; Schneider, M. // Zeitschrift für Rheumatologie;Nov2010, Vol. 69 Issue 9, p780 

    Over the past years, biological therapies, especially anti-TNF-α antibody therapy has emerged as a treatment approach in patients who have failed to achieve or maintain remission with tradional DMARDs. Women suffering from inflammatory arthritis may need to continue therapy throughout...

  • Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Lehman, Thomas J. A.; Singh, Chahait; Ramanathan, Anusha; Alperin, Risa; Adams, Alexa; Barinstein, Laura; Moorthy, Nandini // Pediatric Rheumatology; 

    Background Although the combination of cyclophosphamide and rituximab has been utilized in case reports, there are no previous reports of the long term outcome of SLE treated systematically with this regimen. We report a pilot study to evaluate the efficacy of a systematically administered...

  • Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Ozaki, Shoichi; Atsumi, Tatsuya; Hayashi, Taichi; Ishizu, Akihiro; Kobayashi, Shigeto; Kumagai, Shunichi; Kurihara, Yasuyuki; Kurokawa, Manae; Makino, Hirofumi; Nagafuchi, Hiroko; Nakabayashi, Kimimasa; Nishimoto, Norihiro; Suka, Machi; Tomino, Yasuhiko; Yamada, Hidehiro; Yamagata, Kunihiro; Yoshida, Masaharu; Yumura, Wako // Modern Rheumatology (Springer Science & Business Media B.V.);Jun2012, Vol. 22 Issue 3, p394 

    We (JMAAV [Japanese patients with MPO-ANCA-associated vasculitis] Study Group) performed a prospective, open-label, multi-center trial to evaluate the usefulness of severity-based treatment in Japanese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated...

  • Serum Viscosity and Hyperviscosity Syndrome in IgG Multiple Myeloma. Pruzanski, W.; Watt, J.G. // Annals of Internal Medicine;Dec72, Vol. 77 Issue 6, p853 

    Focuses on patients with immunoglobulin (IgG) multiple myeloma and hyperviscosity. Clinical manifestations related to hyperviscosity; Hematological and biochemical data of patients with IgG myeloma and serum hyperviscosity; Effect of hyperviscosity syndrome on the course of IgG myeloma.

  • Essential Type II Cryoglobulinemia in a 22-Year-Old African-American Female. Mary Mayo; Alan Lipe; Ganesh Kudva // Laboratory Medicine;Oct2008, Vol. 39 Issue 10, p597 

    Cryoglobulins are either immunoglobulins or a mixture of immunoglobulins and complement components that precipitate out of a patient's plasma or serum at temperatures below 37°C. In rare cases, immunoglobulins do not precipitate, but form a gel upon cooling. Cryoglobulinemia, or the presence...

  • Ä°ntraepidermal Otoimmün Büllöz Hastalıkların Tedavisi. Kaya, Tamer İrfan // Archives of the Turkish Dermatology & Venerology / Turkderm;2011 Supplement 1, Vol. 45, p44 

    Pemfigus is an autoimmune bullous skin disease, characterized by intraepidermal blisters. It is a severe and potentially life-threatening chronic disease with blisters and erosions on the mucosae and the skin. Treatment options do not differ for two most common types of pemphigus, pemphigus...

  • Autoimuna hemolitička anemija refraktorna na kortikosteroidnu i visoko dozaűnu imunoglobulinsku terapiju. Hasanbegović, Edo // Medicinski Arhiv;2008, Vol. 62 Issue 1, p56 

    We report about very rare case of autoimune hemolytic anemia ( AIHA) with «warm» antibodies in eight months old boy. Diagnosis was set up according blood picture results, distinct anaemia in blood picture, positive Coombs test ( IgG) for «warm» antibodies. Therapy with high doses of...

  • Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener's granulomatosis. Huchzermeyer, Cord; Mardin, Christian; Holbach, Leonard; Zwerina, Jochen; Schett, Georg; Rech, Jürgen // Clinical Rheumatology;Mar2013 Supplement, Vol. 32, p97 

    A 56-year old patient with a history of limited Wegener's granulomatosis presented with signs and symptoms of optic neuritis. Radiologic signs of orbital inflammation were absent. Testing of visual acuity and visual field allowed close monitoring of disease activity. Thus, rapid improvement of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics